Costa Rican OTC Drugmaker Hit for Testing, Stability Program

Drug Industry Daily
A A
The FDA issued a warning letter to a Costa Rican OTC drug manufacturer for testing and other violations. and , an inadequate stability program and risks of cross-contamination netted a Costa Rican OTC drug manufacturer a warning letter from the FDA.

To View This Article:

Login

Subscribe To Drug Industry Daily